Zhimai (Shanghai) Robot Co., Ltd.

admin722025-09-01 21:37:35

Zhimai (Shanghai) Robot Co., Ltd. Company Overview

Zhimai (Shanghai) Robot Co., Ltd. is a Sino-French joint venture established on 18 March 2021 by Shanghai MicroPort MedBot (Group) Co., Ltd. and France-based Robocath S.A.S. Located in the China (Shanghai) Pilot Free Trade Zone, the company focuses on localization, manufacturing, commercialization, and ongoing R&D of the R-ONE® vascular-intervention robotic system. On 8 December 2023, R-ONE® became the first coronary-PCI robot approved by china’s National Medical Products Administration (NMPA), marking the official opening of the domestic robotic-assisted PCI market.

Core Business and Key Technologies

Zhimai’s core business spans the full lifecycle of vascular-intervention robotic systems:

Technology transfer and localization engineering of the R-ONE® platform.
Domestic manufacturing, final assembly, and quality control for the China market.
Commercial operations including marketing, clinical training, installation, service, and distributor management.
Next-generation R&D to expand indications, enable remote PCI over 5G, and integrate AI-based procedural planning.

The R-ONE® system features proprietary bionic dual-finger “twist & push” actuation, 0–360° continuous rotation/translation, sub-millimetric stepping accuracy, single-operator instrument exchange, and sterile single-use covers for rapid setup and infection control.

Market Position and Flagship Product

As the first and only commercially approved coronary-PCI robot in China, R-ONE® positions Zhimai as a leader in the rapidly growing interventional-cardiology robotics market. Clinical data from pivotal multi-center trials led by PLA General Hospital confirmed:

95% reduction in operator radiation exposure.
Accelerated learning curve for new interventional cardiologists.
Effective treatment of complex lesions including bifurcations, tortuous vessels, long diffuse disease, calcifications, and sub-total occlusions.
World-first 5G-enabled remote PCI procedures in 2024, including consecutive multi-stent implantations.

Leveraging MicroPort’s cardiovascular ecosystem, Zhimai secured its first commercial orders and completed two domestic installations in 2024. The company continues to expand its distributor network and scale local production to meet market demand.

Contact Information

Website: Currently under development (inquiries via parent company)

Address: Room 1817, Building 1, 1601 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone (actual floor 16), Pudong, Shanghai 201203, China

Phone: +86 21 3895 4600

Email: medbot@microport.com

Keywords: Zhimai (Shanghai) Robot Co., Ltd., R-ONE®, vascular-intervention robot, PCI, coronary robotics, Shanghai MicroPort MedBot, Robocath, interventional cardiology robotics